title: Differential regulation of adiponectin secretion from cultured human omental and subcutaneous adipocytes: effects of insulin and rosiglitazone.
abstract: Adiponectin is an adipocyte-derived plasma protein with insulin-sensitizing and antiatherosclerotic properties. Because adipose tissue depots differ in the strength of their association with the adverse metabolic consequences of obesity, we studied the secretion of adiponectin in vitro from paired samples of isolated human omental and sc adipocytes and its regulation by insulin and rosiglitazone. Cells were incubated for 12 or 24 h with and without treatment with 100 nM insulin, 8 micro M rosiglitazone, or both combined; adiponectin secreted into the culture medium was measured by a RIA with a human adiponectin standard and normalized for cellular DNA content. Secretion of adiponectin by omental cells was generally higher than sc cells and showed a strong negative correlation with body mass index (r = -0.78;P = 0.013). In contrast, secretion from the sc cells was unrelated to body mass index. Compared with sc-derived adipocytes, adiponectin secretion from omental cells was increased by insulin or rosiglitazone alone and was up to 2.3-fold higher following combined treatment with insulin and rosiglitazone, whereas secretion from sc adipose cells was unaffected by these treatments. These data suggest that reduced secretion from the omental adipose depot may account for the decline in plasma adiponectin observed in obesity. Furthermore, enhanced adiponectin secretion from fat cells derived from the visceral compartment in response to rosiglitazone alone or in combination with insulin may play a role in some of the systemic insulin-sensitizing and antiinflammatory properties of the thiazolidinediones.
authors.affiliation: Dorrance H. Hamilton Research Laboratories, Division of Endocrinology, Diabetes, and Metabolic Diseases, Department of Medicine, Jefferson Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA.
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Motoshima
authors.forename: Xiangdong
authors.initials: X
authors.lastname: Wu
authors.forename: Madhur K
authors.initials: MK
authors.lastname: Sinha
authors.forename: V Elise
authors.initials: VE
authors.lastname: Hardy
authors.forename: Ernest L
authors.initials: EL
authors.lastname: Rosato
authors.forename: Donna J
authors.initials: DJ
authors.lastname: Barbot
authors.forename: Francis E
authors.initials: FE
authors.lastname: Rosato
authors.forename: Barry J
authors.initials: BJ
authors.lastname: Goldstein
mesh_terms: D017667:Adipocytes / Q000378:metabolism*; D052242:Adiponectin; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015992:Body Mass Index; D002478:Cells, Cultured; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology*; D007328:Insulin / Q000494:pharmacology*; D036341:Intercellular Signaling Peptides and Proteins; D008875:Middle Aged; D009852:Omentum / Q000166:cytology*; D011506:Proteins / Q000378:metabolism*; D000077154:Rosiglitazone; D040521:Subcutaneous Tissue / Q000378:metabolism*; D013844:Thiazoles / Q000494:pharmacology*; D045162:Thiazolidinediones
chemical_list: D052242:Adiponectin; D007004:Hypoglycemic Agents; D007328:Insulin; D036341:Intercellular Signaling Peptides and Proteins; D011506:Proteins; D013844:Thiazoles; D045162:Thiazolidinediones; D000077154:Rosiglitazone